Physician profile
Matthew S Walker
NPI 1023336724
$12,500.14
in general payments reported to CMS, 2019-2025
50 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,030 · 2020: $643 · 2021: $1,670 · 2022: $2,310 · 2023: $1,999 · 2024: $1,876 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,846.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,307.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,154.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,085.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,062.74 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $1,032.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $888.43 | 2019-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Astrazeneca Pharmaceuticals LP | $698.98 | 2019-2025 | Farxiga, Tezspire, Airsupra |
| Merck Sharp & Dohme LLC | $619.20 | 2019-2025 | Belsomra, Steglatro, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $453.32 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $377.58 | 2023-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.41 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $341.95 | 2022-2025 | |
| Amgen INC. | $291.50 | 2019-2024 | Repatha, Otezla, Prolia |
| Sanofi-Aventis U.S. LLC | $269.61 | 2019-2025 | |
| Abbott Laboratories | $244.64 | 2021-2025 | Freestyle Libre 3 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.